![Surish Shanmugam MBChB, MSc, RCP(UK) (Medical Oncology)](https://res.cloudinary.com/els-assets/image/upload/c_fill_pad,f_auto,g_auto,h_150,q_auto,w_120/v1/practice-update/remote-media/contentimage/37354.jpg)
Surish P. Shanmugam MBChB, MSc, RCP(UK) (Medical Oncology)
Master's student, Harvard Medical School, Boston, MassachusettsDr. Surish Shanmugam obtained his medical degree from the University of Glasgow, UK and subsequently obtained a Master’s degree in Drug Discovery & Protein Biotechnology from the University of Edinburgh, UK. He is a UK board certified medical oncologist with a keen interest in Oncology Drug Discovery and Translational Research and has also spent around 6 years working in industry as a pharmaceutical physician/oncologist, specifically on GU and GI oncology as well as leukemia. He has recently undertaken a Master's degree focused on cancer translational research at Harvard Medical School and joined Dr. Kent Mouw’s lab at the Dana Farber Cancer Institute to pursue wet lab/translational research in the urothelial cancer (UC) space, specifically in relation to Homologous Recombination Repair deficient and Nucleotide Excision Repair deficient UC respectively.
Dr. Surish also has a side interest in Health Economics and holds a Master’s degree in Health Economics & Pharmaco-economics. As much as he is deeply passionate about cancer research, he is equally passionate about finding practical and sustainable solutions that will greatly increase patient access to high quality cancer treatments.
Disclosures
No disclosures reported.Recent Contributions to PracticeUpdate:
- Perioperative Immunotherapy for High-Risk Muscle-Invasive Urothelial Cancer: Insights From CheckMate 274
- Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma
- Outcomes of Maintenance Treatment With the Poly ADP–Ribose Polymerase Inhibitor Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma